Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced the approval of its Rivastigmine Transdermal Patch, a treatment for mild to moderate Alzheimer’s disease, by China’s National Medical Products Administration. This patch, which is the first of its kind produced domestically in China, offers a stable release of medication, potentially improving cognitive function and patient adherence to treatment. The company aims to alleviate the burden on patients and families dealing with Alzheimer’s, a condition affecting an estimated 50 million people globally.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
